Gapping up
In reaction to earnings/guidance:
- BRZE +12.2%, ORCL +11.7%, BFH +5% (guidance), CNM +2.9%, LICY +1.6%, ANF +1.5% (guidance), TWI +1.3% (guidance), COTY +1.1%
Other news:
- EYE +13.8% (appointed to join S&P SmallCap 600)
- WULF +7.5% (announced recent financing actions and near-term ramp of digital infrastructure)
- CLR +7.5% (announces receipt of "take private" proposal from Hamm Family of $70/share)
- OSG +6.8% (authorized repurchase of 5 mln shares)
- HYZN +6.1% (acquires Orten Betriebs GmbH and Orten Electric Trucks GmbH)
- MNTS +3.4% (provided Mission Update for Vigoride-3 spacecraft)
- GAN +3.3% (extends its previously authorized $5 mln share repurchase program to November 30 2022)
- MOR +1.7% (entered into collaboration with Pfizer [PFE] and Incyte [INCY] for Monjuvi and TTI-622)
- ICFI +1.2% (awarded a $30 mln contract by U.S. Department of Defense Defense Health Agency)
- ALNY +1.2% (receives FDA approval for AMVUTTRA)
- UNVR +1% (subsidiary announces new distribution agreement with BOAI NKY Pharmaceuticals)
- RMD +1% (acquires MEDIFOX DAN for $1 bln)
Analyst comments:
- SLCA +3.8% (upgraded to Outperform from In-line at Evercore ISI)
- PBF +3.5% (upgraded to Overweight from Equal Weight at Wells Fargo)
- NOK +3.1% (upgraded to Buy from Neutral at Citigroup)
- NTAP +2.4% (upgraded to Buy from Hold at Deutsche Bank)
- TSCO +1.3% (upgraded to Buy from Neutral at BofA Securities)
- BGS +1.2% (upgraded to Neutral from Underweight at Piper Sandler)
